Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma

Drug-induced immune hemolytic anemia (DIIHA) is a rare condition with an increasing incidence associated with the frequent use of certain drugs. An 85-year-old woman with lung adenocarcinoma prescribed alectinib complained of dyspnea on exertion at our hospital. Based on her laboratory tests results...

Descripción completa

Detalles Bibliográficos
Autores principales: Okumoto, Joe, Sakamoto, Shinjiro, Masuda, Takeshi, Yamaguchi, Kakuhiro, Horimasu, Yasushi, Miyamoto, Shintaro, Nakashima, Taku, Iwamoto, Hiroshi, Fukushima, Noriyasu, Fujitaka, Kazunori, Hamada, Hironobu, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946499/
https://www.ncbi.nlm.nih.gov/pubmed/32999219
http://dx.doi.org/10.2169/internalmedicine.4241-19
Descripción
Sumario:Drug-induced immune hemolytic anemia (DIIHA) is a rare condition with an increasing incidence associated with the frequent use of certain drugs. An 85-year-old woman with lung adenocarcinoma prescribed alectinib complained of dyspnea on exertion at our hospital. Based on her laboratory tests results on admission, we focused on the clinical course of anemia and hemolysis progression after alectinib administration. The patient's anemia and hemolysis gradually improved after discontinuation of alectinib, leading to a diagnosis of alectinib-induced IHA, presented here as the first case encountered in a patient with lung adenocarcinoma. Furthermore, we discuss the importance of correlating clinical laboratory findings in DIIHA.

Ejemplares similares